Insider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

TG Therapeutics Trading Down 0.9%

NASDAQ TGTX opened at $32.16 on Friday. The firm’s 50 day moving average price is $32.38 and its two-hundred day moving average price is $35.63. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. TG Therapeutics, Inc. has a twelve month low of $21.16 and a twelve month high of $46.48. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 86.92 and a beta of 1.88.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million for the quarter, compared to analysts’ expectations of $147.76 million. During the same quarter in the prior year, the firm earned $0.04 earnings per share. The company’s revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TGTX. Wellington Management Group LLP lifted its stake in shares of TG Therapeutics by 1,809.9% in the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after purchasing an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at $30,545,000. Nuveen LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at $29,442,000. Woodline Partners LP acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at $21,021,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of TG Therapeutics by 1,221.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock valued at $15,191,000 after purchasing an additional 390,137 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.